Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Insomnia (Self-reported, Non-diagnosed),...
Phase NA
Enrollment 94
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to evaluate the feasibility and the effect of self-acupressure on improving insomnia among the elderly with hypertension who reported insomnia (using the Insomnia Severity Index questionnaire) The main questions it aims to answer are: * Is the proposed intervention feasible to deliver to the target population in terms of recruitment, retention, adherence, and completion of outcome assessments? * Does self-acupressure improve insomnia among the elderly with hypertension? Researchers will compare participants in the self-acupressure group (practice acupressure at home for 28 days) and the enhanced standard care group to see the effectiveness of acupressure in improving insomnia for hypertensive elderly individuals. Participants in the self-acupressure group will be instructed how to locate and perform acupressure, then they will be asked to practice acupressure at home for 28 days (once a day). Participants in the enhanced standard care group will receive training on how to apply sleep hygiene rules and will be asked to follow sleep hygiene rules for 28 days.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Other: Acupressure to improve insomnia — The acupressure protocol of the intervention was developed and validated by 6 traditional and hypertensive experts. Participants will be ask to perform acupressure with 6 acupoint including: Baihui (GV20), Yintang (GV29), Shenmen (HT\&0\< Sanyinjao (SP6), Zushalin (ST36) at nightime (30 mins before going to bed) in 28 days.Each acupoint must be stimulated in 2 mins.

Primary Outcomes

  • Insomnia severity (Insomnia severity will be measured at 3 time points: Baseline, Week 4, and Week 8)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-08-30
Completion: 2027-03-30
Eligibility
Age: 60 Years and older
Sex: ALL
Volunteers: false
Enrollment: 94 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Phenikaa University
Contact Information
Study Contact:
Huong Hoang, PhD
+84 0982501850
huong.hoangthixuan@phenikaa-uni.edu.vn
Huong Hoang
+84 0982501850
huong.hoangthixuan@phenikaa-uni.edu.vn
Son Tay general hospital
Interventions
  • Other: Acupressure to improve insomnia — The acupressure protocol of the intervention was developed and validated by 6 traditional and hypertensive experts. Participants will be ask to perform acupressure with 6 acupoint including: Baihui (GV20), Yintang (GV29), Shenmen (HT\&0\< Sanyinjao (SP6), Zushalin (ST36) at nightime (30 mins before going to bed) in 28 days.Each acupoint must be stimulated in 2 mins.
Study Locations (1 sites)
Son Tay general hospital, Hanoi, Son Tay 100000 Vietnam
Eligibility Criteria
Inclusion Criteria: * Hypertention patient who are ≥ 60 years old * Having Insomnia Severity Index score ≥ 11 * Having Karnofsky score ≥ 80. Exclusion Criteria: * Patients who are currently participating in clinical trials for the treatment of insomnia. * Patients who are currently receiving pharmacological treatment for insomnia. * Patients with concomitant cardiovascular conditions, such as heart failure; patients with an implanted pacemaker; patients who have an indication for catheter-based cardiovascular intervention; or patients who have an indication for cardiovascular surgery. * Patients with psychiatric disorders, such as depression, generalized anxiety disorder, or bipolar disorder.
Conditions Chronic Thromboembolic Pulmonary Hyperte...
Phase Not Applicable
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

Chronic ThromboEmbolic Pulmonary Hypertension (CTEPH) is a rare but severe complication of pulmonary embolism (PE). CTEPH is evoked in patients with persistent dyspnea. According to international guidelines, symptomatic patients with perfusion defects on lung scan and Pulmonary Hypertension (PH)-likely transthoracic echo (TTE) must be evaluated in Pulmonary Hypertension (PH)-centers with right heart catheterism, to confirm or rule out the presence of precapillary Pulmonary Hypertension (PH), and precise the group of Pulmonary Hypertension (PH).

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Biological: blood sample — to realize proteomic analysis.

Primary Outcomes

  • Proteomic pattern associated with the diagnosis of Chronic thromboembolic pulmonary hypertension (CTEPH) (Day: 0)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-11-09
Completion: 2027-05
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre Hospitalier Universitaire de Saint Etienne
Principal Investigators:
  • Laurent BERTOLETTI, PhD (PRINCIPAL_INVESTIGATOR) - Centre Hospitalier Universitaire de Saint Etienne
Contact Information
Study Contact:
Laurent BERTOLETTI, MD PhD
(0)477127770
laurent.bertoletti@chu-st-etienne.fr
Carine LABRUYERE
(0)477120826
carine.labruyere@chu-st-etienne.fr
Laurent BERTOLETTI, MD PhD
CHU de SAINT-ETIENNE
Interventions
  • Biological: blood sample — to realize proteomic analysis.
Study Locations (1 sites)
CHU de SAINT-ETIENNE, Saint-Etienne, 42055 France
Eligibility Criteria
Inclusion Criteria: * Patient with a suspicion of Chronic thromboembolic pulmonary hypertension (CTEPH) with a combination of a perfusion lung scan and transthoracic perfusion scan and transthoracic echocardiography compatible with the diagnosis (according to French recommendations) * Patients who require a right heart catheterization. * Patient affiliated or entitled to a social security plan * Patient having received informed information about the study informed about the study Exclusion Criteria: * Patient with a normal perfusion lung scan * Person under legal guardianship
Conditions Cardiovascular Disease Prevention, Cardi...
Phase NA
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this longitudinal study is to investigate the role of virtual health coaching on mitigation of cardiometabolic disease risk in an underserved, food insecure population. The main questions it aims to answer are: * Does longitudinal, individualized health coaching directed at lifestyle modification reduce patient 10-year risk of heart attack or stroke? * Does longitudinal, individualized health coaching directed at lifestyle modification reduce rates of hypertension, hyperlipidemia, and diabetes? * Does longitudinal, individualized health coaching directed at lifestyle modification improve accessibility to healthcare? Researchers will investigate the effects of regularly scheduled health coaching sessions on composite cardiometabolic risk profile as well as individual modifiable cardiovascular risk factors. Participants will: * Participate in in-person cardiovascular screening, occuring at the time of enrollment, months 3 and 6. * Engage in virtual health coaching sessions to talk about diet, exercise, weight loss, blood pressure and diabetes control, and accessibility to healthcare * Keep a log of their blood pressure

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Longitudinal, Individualized Health Coaching — During in-person events and screening - occurring at the initial screening, 3, and 6 months - patients will receive individualized health coaching by on-site physicians and nurse practitioners specializing in lifestyle medicine. Patients will receive virtual health coaching sessions, conducted by medical students and overseen by a licensed health coach, directed at individualized lifestyle modification relevant to the patient's cardiometabolic health profile. Interventions will include but not limited to: changes in diet, exercise, smoking, and drinking status. Patients will receive blood pressure cuffs and will be instructed as to how to measure and keep a log of their blood pressure to be reviewed during health coaching sessions. Sessions will occur biweekly for the first month and monthly for the following 2 months. Sessions will last approximately 15 minutes in length.

Primary Outcomes

  • 10 - Year Atherosclerotic Cardiovascular Disease Risk Score (From enrollment to the end of study participation at 6 months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03-01
Completion: 2027-07-01
Eligibility
Age: 40 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Rush University Medical Center
Collaborators: The Physicians Foundation
Principal Investigators:
  • Daniel Luger, MD (PRINCIPAL_INVESTIGATOR) - Rush University Medical Center
Contact Information
Study Contact:
Daniel Luger, MD
\(708) 660-2328
daniel_luger@rush.edu
Daniel Luger, MD
(312) 942-5020
daniel_luger@rush.edu
Rush University Medical Center
Interventions
  • Behavioral: Longitudinal, Individualized Health Coaching — During in-person events and screening - occurring at the initial screening, 3, and 6 months - patients will receive individualized health coaching by on-site physicians and nurse practitioners specializing in lifestyle medicine. Patients will receive virtual health coaching sessions, conducted by medical students and overseen by a licensed health coach, directed at individualized lifestyle modification relevant to the patient's cardiometabolic health profile. Interventions will include but not limited to: changes in diet, exercise, smoking, and drinking status. Patients will receive blood pressure cuffs and will be instructed as to how to measure and keep a log of their blood pressure to be reviewed during health coaching sessions. Sessions will occur biweekly for the first month and monthly for the following 2 months. Sessions will last approximately 15 minutes in length.
Study Locations (1 sites)
Rush University Medical Center, Chicago, Illinois 60612 United States
Eligibility Criteria
Inclusion: * Patient is a participant at a CHI sponsored, community screening event * Patient provides informed consent and willingness to participate for the duration of the study * English or Spanish speaking * Age 40-75 years old * At least 1 cardiometabolic risk factor at suboptimal level, defined as one or more of the following at initial screening: * Systolic BP greater than 130mmHg and/or diastolic BP greater than 80mmHg. * Body mass index (BMI) greater than 30 〖kg/m〗\^2 * Total cholesterol greater than 200 mg/dL * Triglycerides greater than 150 mg/dL * Low density lipoprotein (LDL) greater than 130 mg/dL * High density lipoprotein (HDL) less than 40 mg/dL in men or less than 50 mg/dL in women * Hemoglobin A1c greater than or equal to 5.7% * 10-year ASCVD score greater than 5% * Access to a telehealth compatible device Exclusion: * Adults unable to provide informed consent or unwilling to participate for study duration * Speaks language other than English or Spanish * Younger than 40 years old or older than 75 years old * All cardiometabolic risk factors at optimal levels * No telehealth compatible device * Pregnant patients
Conditions Portal Hypertension, Chronic Liver Disea...
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this investigator-initiated, single-arm, prospective study is to evaluate the accuracy, safety, and feasibility of endoscopic ultrasound-guided portal pressure gradient (EUS-PPG) measurement as a potential alternative to the traditional hepatic venous pressure gradient (HVPG) method in patients with portal hypertension due to chronic liver disease. The main questions it aims to answer are: * What is the correlation between EUS-PPG and HVPG measurements in patients with portal hypertension due to cirrhosis? * Can EUS-PPG serve as a reliable and less invasive alternative to HVPG for assessing portal pressure? * What are the safety outcomes associated with EUS-PPG compared to HVPG? Researchers will compare EUS-PPG measurements with HVPG measurements within the same patients to assess whether EUS-PPG provides accurate and clinically comparable portal pressure readings while reducing procedural risks. Participants will: * Be adults aged 18 to 85 with a history of liver disease and portal hypertension or suspected cirrhosis requiring HVPG measurement. * Undergo both EUS-PPG and HVPG measurements within a seven-day window to allow for direct comparison of results. * Receive standard clinical care for their condition, including routine diagnostic evaluations and portal hypertension management as needed. * Be monitored for safety outcomes, including adverse events such as bleeding, infection, perforation, and any other complications related to the procedure. * Provide relevant demographic and clinical data, including liver disease history, Child-Pugh and MELD scores, and portal hypertension-related complications such as varices or ascites.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: Endoscopic Ultrasound-Guided Portal Pressure Gradient (EUS-PPG) Measurement — Endoscopic Ultrasound-Guided Portal Pressure Gradient (EUS-PPG) measurement is a minimally invasive, ultrasound-based diagnostic procedure designed to assess portal hypertension in patients with chronic liver disease. Using an endoscopic ultrasound (EUS) probe, and a fine-needle aspiration (FNA) needle (EchoTip® Insight™) is used to directly measure intravascular pressures. Unlike the standard hepatic venous pressure gradient (HVPG) measurement, EUS-PPG provides direct pressure readings, does not require catheterization of the hepatic vein, and eliminates the need for radiation, iodinated contrast, and interventional radiology. This study aims to evaluate the accuracy, feasibility, and safety of EUS-PPG compared to HVPG.
  • Diagnostic Test: Hepatic Venous Pressure Gradient (HVPG) Measurement — Hepatic Venous Pressure Gradient (HVPG) measurement is the current gold standard for assessing portal hypertension in patients with chronic liver disease. The procedure involves catheterization of the hepatic vein via the jugular or femoral vein, where free hepatic venous pressure (FHVP) and wedged hepatic venous pressure (WHVP) are measured using a pressure transducer. HVPG is an indirect measure of portal pressure and requires fluoroscopy, radiation exposure, and specialized interventional radiology equipment. While widely used in clinical practice, HVPG has limitations, including the need for a hospital setting, potential patient discomfort, and limited feasibility in certain cases. This study will compare HVPG to EUS-PPG to determine whether EUS-PPG can serve as a less invasive and more accessible alternative.

Primary Outcomes

  • Correlation between the portosystemic pressure gradient (PPG) measured directly via endoscopic ultrasonography (EUS-PPG) and measured via the hepatic venous pressure gradient (HVPG). (7 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-04-16
Completion: 2026-12
Eligibility
Age: 18 Years – 85 Years
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fundacio Privada Mon Clinic Barcelona
Contact Information
Study Contact:
Principal Investigator
+34932275400
contacta@clinic.cat
Hospital Clinic de Barcelona
Juan Carlos García-Pagan
Hospital Clinic de Barcelona
Interventions
  • Diagnostic Test: Endoscopic Ultrasound-Guided Portal Pressure Gradient (EUS-PPG) Measurement — Endoscopic Ultrasound-Guided Portal Pressure Gradient (EUS-PPG) measurement is a minimally invasive, ultrasound-based diagnostic procedure designed to assess portal hypertension in patients with chronic liver disease. Using an endoscopic ultrasound (EUS) probe, and a fine-needle aspiration (FNA) needle (EchoTip® Insight™) is used to directly measure intravascular pressures. Unlike the standard hepatic venous pressure gradient (HVPG) measurement, EUS-PPG provides direct pressure readings, does not require catheterization of the hepatic vein, and eliminates the need for radiation, iodinated contrast, and interventional radiology. This study aims to evaluate the accuracy, feasibility, and safety of EUS-PPG compared to HVPG.
  • Diagnostic Test: Hepatic Venous Pressure Gradient (HVPG) Measurement — Hepatic Venous Pressure Gradient (HVPG) measurement is the current gold standard for assessing portal hypertension in patients with chronic liver disease. The procedure involves catheterization of the hepatic vein via the jugular or femoral vein, where free hepatic venous pressure (FHVP) and wedged hepatic venous pressure (WHVP) are measured using a pressure transducer. HVPG is an indirect measure of portal pressure and requires fluoroscopy, radiation exposure, and specialized interventional radiology equipment. While widely used in clinical practice, HVPG has limitations, including the need for a hospital setting, potential patient discomfort, and limited feasibility in certain cases. This study will compare HVPG to EUS-PPG to determine whether EUS-PPG can serve as a less invasive and more accessible alternative.
Study Locations (1 sites)
Hospital Clinic de Barcelona, Barcelona, 08036 Spain
Eligibility Criteria
Inclusion Criteria: * Subjects must be 18 to 85 years of age inclusive, at the time of signing the informed consent form. * Subjects who have a history of liver disease and portal hypertension or suspected cirrhosis requiring HVPG measurement. * Subjects capable of giving signed informed consent. Exclusion Criteria: * Pregnancy. * Significant bleeding risk (International Normalized Ratio (INR) \> 1.5 OR platelet count \< 50000). * Presence of active gastrointestinal bleeding at the time of screening * History of any blood thinner consumption (e.g. warfarin, heparin, novel roal anticoagulants) within the last 5 days. * Presence of massive ascites causing abdominal distension or requiring frequent therapeutic paracentesis. * Subjects having received previous Transjugular Intrahepatic Portosystemic Shunt (TIPS) or Surgical Portosystemic Shunt. * Hepatocellular carcinoma not meeting Milan Criteria. * Presence of portal vein thrombosis or another suspected component of presinusoidal portal hypertension. * Presence of extra-hepatic cancer, terminal disease, or severe comorbidities significantly limiting life expectancy or affecting study participation. * Stenosis or surgical anatomical alterations of the gastrointestinal tract that could preclude endoscopic access with the echoendoscope.
Conditions Chronic Lung Disease, Pulmonary Hyperten...
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

Prospective observational study to determine if the PVD-B65 risk score for one-year mortality in patients with chronic lung disease and pulmonary hypertension (CLD-PH) can accurately risk stratify these patients and successfully predict one-year mortality from time of pulmonary hypertension diagnosis. PVD-B65 risk score was developed in a retrospective cohort of patients with CLD-PH, utilizing the presence of pulmonary fibrosis without emphysema, pulmonary vascular resistance (PVR) \> 5 woods units (WU), 6-minute walk distance (6MWD) \< 150 meters, B-natriuretic type peptide (BNP) \> 200 pg/mL or N-terminal pro-natriuretic type peptide (NT-proBNP) \> 300 pg/dL, and age \> 65 years as the score components.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: Observational Study — * assignment of PVD-B65 score derived from standard of care testing * no therapeutic intervention or other treatment

Primary Outcomes

  • Prediction of one year mortality (One year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-09-01
Completion: 2028-09-01
Eligibility
Age: 18 Years – 99 Years
Sex: ALL
Volunteers: Not specified
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Temple University
Contact Information
Study Contact:
Shameek Gayen, MD
267-990-3630
shameek.gayen@tuhs.temple.edu
Shameek Gayen, MD
267-990-3630
shameek.gayen@tuhs.temple.edu
Temple University Hospital
Interventions
  • Diagnostic Test: Observational Study — * assignment of PVD-B65 score derived from standard of care testing * no therapeutic intervention or other treatment
Study Locations (1 sites)
Temple University Hospital, Philadelphia, Pennsylvania 19140 United States
Eligibility Criteria
Inclusion Criteria: * Eligibility criteria 1. Adult patients ≥ 18 years of age with chronic lung disease diagnosed via CT chest and/or PFT data and pre-capillary pulmonary hypertension diagnosed via right-heart catheterization (RHC, mPAP \> 20 mmHg, PVR \> 2 WU, and PCWP ≤ 15 mmHg) 1. Chronic lung disease diagnoses will include: COPD, IPF, other pulmonary fibrosis, non-fibrotic ILD, combined pulmonary fibrosis and emphysema, and advanced pulmonary sarcoidosis with parenchymal involvement 2. PFT criteria will include an FEV1/FVC \< 0.70 for the diagnosis of COPD 2. Willingness to make return visits and be available by telephone for the duration of the study. 3. Ability to participate in necessary testing, including ambulatory testing Exclusion Criteria: * Exclusion criteria 1. Patients with pulmonary hypertension but without associated chronic lung disease (i.e. idiopathic or group 1 PAH, PH with post-capillary component defined as PCWP \> 15 mmHg or group 2 PAH, CTEPH or group 4 PH, group 5 PH aside from sarcoidosis with parenchymal involvement) 2. Patients with uncontrolled severe systemic disease that could influence life expectancy (i.e. uncontrolled cardiovascular disease, active malignancy, etc.) 3. Prior lung and/or heart transplantation
Conditions Cardiovascular Diseases, Hypertension, D...
Phase NA
Enrollment 45000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

U-SCREEN is a randomized controlled trial evaluating whether systematic home-based multimodal screening for cardiovascular risk conditions, offered to residents in Region Uppsala turning 50, 55, 60, 65, 70 or 75 years of age, can identify clinically actionable cardiovascular risk factors more effectively than usual care. Participants randomized to the screening arm receive a home blood pressure measurement device, a dried blood spot sampling kit (for ApoB, HbA1c and creatinine), and a digital questionnaire. The control arm receives usual care. Recruitment runs 2024-2027 with a target identification of 10,000 cardiovascular risk conditions.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Screening Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Home-based multimodal cardiovascular screening — Self-administered home-based screening program: 7-day home BP, DBS biomarker self-sampling, digital questionnaire; structured digital return of results; threshold-based initiation of guideline-recommended pharmacotherapy and referral to clinical care.

Primary Outcomes

  • Rate of total major adverse cardiovascular events over 10 years (Within 10 years after randomization)
  • Number of initiated guideline-recommended pharmacotherapies for cardiovascular risk factors within 12 months (Within 12 months after randomization)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-02-01
Completion: 2037-12
Eligibility
Age: 50 Years – 75 Years
Sex: ALL
Volunteers: true
Enrollment: 45000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Johan Sundström
Collaborators: Region Uppsala Public Health and Care
Principal Investigators:
  • Johan Sundström, MD, PhD (PRINCIPAL_INVESTIGATOR) - Uppsala University
  • Anders Wanhainen, MD, PhD (PRINCIPAL_INVESTIGATOR) - Uppsala University
Contact Information
Study Contact:
Johan Sundström, MD, PhD
+46 70 422 52 20
johan.sundstrom@uu.se
Sundström
+46 70 422 52 20
johan.sundstrom@uu.se
Uppsala University Hospital
Sundström
Uppsala University Hospital
Interventions
  • Behavioral: Home-based multimodal cardiovascular screening — Self-administered home-based screening program: 7-day home BP, DBS biomarker self-sampling, digital questionnaire; structured digital return of results; threshold-based initiation of guideline-recommended pharmacotherapy and referral to clinical care.
Study Locations (1 sites)
Uppsala University Hospital, Uppsala, 751 85 Sweden
Eligibility Criteria
Inclusion Criteria: * Resident in Region Uppsala, Sweden * Turning 50, 55, 60, 65, 70 or 75 years during recruitment period * Able to provide informed consent Exclusion Criteria: * Inability to provide informed consent * Protected identity
Conditions Preeclampsia (PE), Pregnancy
Phase Not Applicable
Enrollment 250
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

Preeclampsia (PE) is a serious pregnancy complication characterized by new-onset hypertension and signs of maternal organ dysfunction, often accompanied by placental abnormalities and systemic endothelial dysfunction. PE is associated with adverse maternal and perinatal outcomes and confers an increased long-term risk of cardiovascular and metabolic disease for both mother and offspring. This prospective observational cohort study aims to establish a longitudinal pregnancy and birth cohort of women diagnosed with preeclampsia. Pregnant women with a clinical diagnosis of PE according to current obstetric guidelines will be recruited at their initial presentation either in the in- or outpatient clinic or in the delivery ward, respectively and followed through late pregnancy, delivery, and early postpartum. Participants will undergo study visits during pregnancy, sample collection at delivery, and a postpartum visit 8-12 weeks after birth. Clinical data, physical measurements, questionnaire-based information, and biological samples will be collected from mothers and infants to enable comprehensive phenotyping of pregnancies complicated by preeclampsia. Data and biosamples from this cohort will be used for descriptive and hypothesis-driven analyses and may be compared with data from an existing longitudinal cohort of healthy pregnancies to support interpretation of preeclampsia-associated biological and clinical changes.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Maternal metabolic and cardiometabolic phenotype: hemodynamic assessments 1 (From study enrollment after PE diagnosis through 8-12 weeks postpartum)
  • Maternal metabolic and cardiometabolic phenotype: Adiposity (From study enrollment after PE diagnosis through 8-12 weeks postpartum)
  • Maternal metabolic and cardiometabolic phenotype: hemodynamic assessments 2 (from study enrollment after PE diagnosis through 8-12 weeks postpartum)
  • Maternal metabolic and cardiometabolic phenotype: Cytokine Profile (From study enrollment after PE diagnosis through 8-12 weeks postpartum)
  • Maternal metabolic and cardiometabolic phenotype: Lipid profile (From study enrollment after PE diagnosis through 8-12 weeks postpartum)
  • Maternal metabolic and cardiometabolic phenotype: hemodynamic assessments 3 (From study enrollment after PE diagnosis through 8-12 weeks postpartum)
  • Maternal metabolic and cardiometabolic phenotype: Echocardiography (From study enrollment after PE diagnosis through 8-12 weeks postpartum)
  • Infant outcomes: hemodynamic assessment (At birth and at 8-12 weeks postpartum)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-03-01
Completion: 2036-03
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 250 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical University of Graz
Contact Information
Study Contact:
Christina Stern, Dr.med
+43 316 385 86306
christina.stern@medunigraz.at
Ursula Hiden, PhD
+43 316 385 17837
ursula.hiden@medunigraz.at
Ursula Hiden, PhD
Department of Obstetrics and Gynecology, Medical University of Graz
Interventions
N/A
Study Locations (1 sites)
Department of Obstetrics and Gynecology, Medical University of Graz, Graz, 8036 Austria
Eligibility Criteria
Inclusion Criteria: * Ongoing pregnancy with preeclampsia regardless the gestational age diagnosed for PE Exclusion Criteria: * Maternal or fetal genetic abnormalities
Conditions Elevated Blood Pressure
Phase Not Applicable
Enrollment 52
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

This will be a prospective observational study. The population would be pediatric patients 6 years to \<19 years of age who were referred for elevated blood pressure to investigate if home blood pressure (HBP) can determine blood pressure phenotype (normotensive, hypertensive, masked hypertension, white coat hypertension) as accurately as ambulatory blood pressure monitor (ABPM) in childhood and adolescence.

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Primary Outcomes

  • Determine blood pressure phenotype (6-12 months after enrollment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-03-24
Completion: 2028-01-01
Eligibility
Age: 6 Years – 19 Years
Sex: ALL
Volunteers: Not specified
Enrollment: 52 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Children's Hospital Medical Center, Cincinnati
Principal Investigators:
  • Elaine Urbina (PRINCIPAL_INVESTIGATOR) - Children's Hospital Medical Center, Cincinnati
Contact Information
Study Contact:
Mary Banks
15136362147
mary.banks@cchmc.org
Elaine Urbina
513-636-8265
elaine.urbina@cchmc.org
Cincinnati Children's Hospital
Elaine Urbina
Cincinnati Children's Hospital
Interventions
N/A
Study Locations (1 sites)
Cincinnati Children's Hospital, Cincinnati, Ohio 45229 United States
Eligibility Criteria
Inclusion Criteria: 1. Age 6 years to \<19 years old; 2. Elevated blood pressure defined as 15% lower than the 95%ile BP based on clinical practice guidelines(CPG) but less than stage II hypertension based on CPG; 3. Tolerate ABPM 24 hours; 4. Tolerate HBP; and 5. Can have diabetes mellitus, obstructive sleep apnea, and attention deficit hyperactivity disorder managed by medication. 6. On stable doses of medications known to affect BP such as: 1. Corticosteroids 2. Calcineurin inhibitors 3. Oral decongestants; 7. Clinically stable Exclusion Criteria: 1. On antihypertension medications or treated in the last 6 months; 2. Pregnant; 3. Structural heart disease such as: 1. Obstructive valvular disease 2. Coarctation of the aorta 3. Cardiomyopathy; 4. Other secondary causes such as: 1. Renal artery stenosis 2. Neurological condition with dysautonomia; 5. Recent initiation of medications known to affect BP such as: 1. Corticosteroids 2. Calcineurin inhibitors 3. Oral decongestants;
Conditions Retinal Dystrophies, Retinitis Pigmentos...
Phase Not Applicable
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

Objective perimetry can better monitor visual field defects in retinal dystrophy and Glaucoma patients than conventional subjective perimetry. The PLR ( Pupil Light Reflex to short and long wavelength stimuli should be significantly lower compared to healthy participants in areas of visual field defects in retinal dystrophy and Glaucoma patients.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Primary Outcomes

  • PLR response amplitude and latency (single visit)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2013-12-01
Completion: 2026-12-31
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: true
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sheba Medical Center
Contact Information
Study Contact:
Ygal Rotenstreich, MD
972547898137
Ygal.Rotenstreich@sheba.health.gov.il
Ygal Rotenstreich, MD
97235302880
Ygal.Rotenstreich@sheba.health.gov.il
Sheba Medical Center
Interventions
N/A
Study Locations (1 sites)
Sheba Medical Center, Tel Litwinsky, 52621 Israel
Eligibility Criteria
Inclusion Criteria: * Age 18-80 years old. * Signing informed consent. * Pupillary reflex to light. Exclusion Criteria: 1. Cloudy corneas. 2. Surgical intraocular ophthalmic procedure within the past 30 days. 3. No reactive pupils. 4. Synechia of the iris to the lens after surgery or inflammation. 5. Neovascularization. 6. Axenfeld-Rieger Syndrome. 7. Iris atrophy (ICE syndrome). 8. Iris coloboma. 9. Sphincter damage due to ischemia. 10. Sphincter damage due to trauma (tears of sphincter or diffuse damage to muscle). 11. Sphincter damage due to Herpes Zoster Uveitis. 12. Sphincter damage due to high intraocular pressure. 13. Iris tumor or cyst. 14. Ectropion uvae. 15. Adie's pupil. 16. Third nerve aberrant regeneration of the iris sphincter. 17. RP patients with Optic neuropathy with the potential of producing a positive RAPD (Relative Afferent Pupillary Defect). 18. Chronic use of myotics or mydriatics. 19. Systemic medication that have affect on pupillary reflex . 20. Any condition preventing accurate measurement or examination of the pupil.
Conditions Asymptomatic Hypertension
Phase NA
Enrollment 15
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

This single-center, single-arm quasi-experimental study will assess the feasibility and acceptability of a community health worker (CHW)-led intervention to address social determinants of health (SDOH) among emergency department patients with hypertension. At enrollment, participants (N=15) will complete standardized SDOH surveys in REDCap, and CHWs will facilitate referrals to local community-based organizations that address identified social needs. With participant consent, the study will also include medical record review through EPIC and Healthix to evaluate healthcare utilization-including emergency department visits, hospitalizations, and outpatient encounters-during the one-year period before and after the index ED visit.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Behavioral: Community Health Worker engagement — Engagement with Community Health Worker who will facilitate referrals to local community-based organizations

Primary Outcomes

  • Number of participants on study at 3 months (3 months)
  • Number of intervention engagement (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-12
Completion: 2026-07-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 15 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Icahn School of Medicine at Mount Sinai
Collaborators: National Institute on Minority Health and Health Disparities (NIMHD)
Principal Investigators:
  • Marcee Wilder, MD MPH (PRINCIPAL_INVESTIGATOR) - ISMMS
Contact Information
Study Contact:
Cindy Clesca
212-824-8057
cindy.clesca@mountsinai.org
Marcee Wilder, MD MPH
Icahn School of Medicine at Mount Sinai
Interventions
  • Behavioral: Community Health Worker engagement — Engagement with Community Health Worker who will facilitate referrals to local community-based organizations
Study Locations (1 sites)
Icahn School of Medicine at Mount Sinai, New York, New York 10029 United States
Eligibility Criteria
Inclusion Criteria: * 18 years and older who reside in the 5 boroughs of NYC, * whom speak English or Spanish, * have a known diagnosis of hypertension, and * have uncontrolled hypertension, defined as two measures of systolic blood pressure (SBP) ≥140 mmHg or diastolic blood pressure (DBP) ≥ 90 mmHg obtained during their ED visit. Exclusion Criteria: * Patients who are unable to consent, * pregnant patients, * patients with a history of end stage renal disease, a history of heart failure or a BMI of greater than 50.
Conditions Coarctation of Aorta, High Blood Pressur...
Phase PHASE3
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate the effectiveness and mechanism of action of Losartan in the treatment of coarctation of aorta.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Double

Interventions / Regimen

  • Drug: Losartan — 50mg administered orally once daily for 52 weeks.
  • Drug: Amlodipine — 5mg Amlodipine administered orally once daily for 52 weeks.
  • Drug: Placebo — Oral capsules that contain no active drug ingredients administered orally once daily for 52 weeks.

Primary Outcomes

  • Change in Left Ventricular (LV) Fibrosis (Baseline; Week 52)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-04-01
Completion: 2028-06-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mayo Clinic
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Principal Investigators:
  • Alexander Egbe, MBBS, MPH (PRINCIPAL_INVESTIGATOR) - Mayo Clinic
Contact Information
Study Contact:
ACHD Research Program
(507) 293-2565
RSTACHDRESPRG@mayo.edu
Alexander Egbe, MBBS, MPH
(507) 284-2520
Egbe.Alexander@mayo.edu
ACHD Research Program
(507) 293-2565
RSTACHDRESPRG@mayo.edu
Mayo Clinic in Rochester
Interventions
  • Drug: Losartan — 50mg administered orally once daily for 52 weeks.
  • Drug: Amlodipine — 5mg Amlodipine administered orally once daily for 52 weeks.
  • Drug: Placebo — Oral capsules that contain no active drug ingredients administered orally once daily for 52 weeks.
Study Locations (1 sites)
Mayo Clinic in Rochester, Rochester, Minnesota 55905 United States
Eligibility Criteria
Inclusion Criteria: * B/S1 hypertension * SBP 100-139 average based on 3 office measurements. * Age 18 or Older * Previous COA Repair Exclusion Criteria: * Currently on beta blocker (BB) therapy * Pregnancy/lactating * eGFR\<30 * Hyperkalemia (serum potassium \>5.5mmol/L) * Severe Aortic or Mitral valve stenosis or regurgitation * Epicardial CAD diagnosis * Received antihypertensive medications within the past year
Conditions Breast Cancer Stage III
Phase NA
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of the study is to evaluate treatment outcomes of breast cancer with internal mammary or supraclavicular lymph node metastasis according to total radiation dose of postoperative radiation therapy differentiated by tumor response to neoadjuvant chemotherapy. The main questions it aims to answer are: * 5-year disease-free survival * 5-year overall survival * 5-year locoregional recurrence * Adverse events after radiation therapy * Quality of life Participants will be assessed by multi-dimensional methods before and after radiotherapy: * Disease status evaluation including physical and radiological examination * Quality of life assessment with questionnaires (BREAST-Q) * Adverse event assessment according to CTCAE version 5.0

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Whole breast / chest wall & regional lymph node irradiation — Whole breast / chest wall and corresponding regional lymph node irradiation with dose of 42.4 Gy in 16 fractions
  • Radiation: Internal mammary or supraclavicular lymph node boost — Simultaneous boost to Internal mammary or supraclavicular lymph node area with dose of total 53.6 Gy or 56.0 Gy in 16 fractions, depending on the response after neoadjuvant chemotherapy

Primary Outcomes

  • 5-year disease-free survival (5 years from the initiation of the radiation therapy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-03-16
Completion: 2030-03-16
Eligibility
Age: 19 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Samsung Medical Center
Principal Investigators:
  • Haeyoung Kim, MD, PhD (PRINCIPAL_INVESTIGATOR) - Samsung Medical Center
Contact Information
Study Contact:
Haeyoung Kim, MD, PhD
82-2-3410-2612
haeyoung0131.kim@samsung.com
Haeyoung Kim, MD, PhD
82-2-3410-2612
haeyoung0131.kim@samsung.com
Samsung Medical Center
Interventions
  • Radiation: Whole breast / chest wall & regional lymph node irradiation — Whole breast / chest wall and corresponding regional lymph node irradiation with dose of 42.4 Gy in 16 fractions
  • Radiation: Internal mammary or supraclavicular lymph node boost — Simultaneous boost to Internal mammary or supraclavicular lymph node area with dose of total 53.6 Gy or 56.0 Gy in 16 fractions, depending on the response after neoadjuvant chemotherapy
Study Locations (1 sites)
Samsung Medical Center, Seoul, 06351 South Korea
Eligibility Criteria
Inclusion Criteria: * Female with age 19 or older * Metastasis to internal mammary and/or supraclavicular lymph nodes, assessed by radiological exams and/or biopsy * Underwent neoadjuvant chemotherapy * Pathologic confirmation of invasive breast cancer treated with breast conserving surgery or mastectomy * Eastern Cooperative Oncology Group performance status 0-2 * Informed consent Exclusion Criteria: * Previous history of radiation therapy to the chest * Distant metastasis